NP_004351.1
[Other Products]
NCBI GenBank Nucleotide #
|
[Other Products]
UniProt Primary Accession #
|
[Other Products]
UniProt Secondary Accession #
UniProt Related Accession #
NCBI Official Full Name
cadherin-1 preproprotein
NCBI Official Synonym Full Names
cadherin 1, type 1, E-cadherin (epithelial)
NCBI Official Synonym Symbols
UVO; CDHE; ECAD; LCAM; Arc-1; CD324 [Similar Products]
NCBI Protein Information
cadherin-1; CAM 120/80; E-Cadherin; uvomorulin; cell-CAM 120/80; OTTHUMP00000174868; epithelial cadherin; cadherin 1, E-cadherin (epithelial); calcium-dependent adhesion protein, epithelial
UniProt Protein Name
Cadherin-1
UniProt Synonym Protein Names
CAM 120/80; Epithelial cadherin; E-cadherin; Uvomorulin
UniProt Synonym Gene Names
UniProt Entry Name
CADH1_HUMAN
NCBI Summary for CDH1
This gene is a classical cadherin from the cadherin superfamily. The encoded protein is a calcium dependent cell-cell adhesion glycoprotein comprised of five extracellular cadherin repeats, a transmembrane region and a highly conserved cytoplasmic tail. Mutations in this gene are correlated with gastric, breast, colorectal, thyroid and ovarian cancer. Loss of function is thought to contribute to progression in cancer by increasing proliferation, invasion, and/or metastasis. The ectodomain of this protein mediates bacterial adhesion to mammalian cells and the cytoplasmic domain is required for internalization. Identified transcript variants arise from mutation at consensus splice sites. [provided by RefSeq]
UniProt Comments for CDH1
CDH1: a single-pass type I membrane protein, and calcium dependent cell adhesion proteins. It is a ligand for integrin alpha-E/beta-7, and it colocalizes with DLG7 at sites of cell-cell contact in intestinal epithelial cells. Anchored to actin microfilaments through association with alpha-, beta- and gamma-catenin. Sequential proteolysis induced by apoptosis or calcium influx, results in translocation from sites of cell-cell contact to the cytoplasm. Involved in mechanisms regulating cell-cell adhesions, mobility and proliferation of epithelial cells. Defects in CDH1 are involved in dysfunction of the cell-cell adhesion system, triggering cancer invasion (gastric, breast, ovary, endometrium and thyroid) and metastasis. Has a potent invasive suppressor role.
Protein type: Ubiquitin ligase; Cell adhesion; Motility/polarity/chemotaxis; Membrane protein, integral
Chromosomal Location of Human Ortholog: 16q22.1
Cellular Component: apical junction complex; internal side of plasma membrane; cell surface; focal adhesion; basolateral plasma membrane; lateral loop; integral to membrane; extracellular region; catenin complex; trans-Golgi network; actin cytoskeleton; cell-cell adherens junction; apical part of cell; perinuclear region of cytoplasm; cytoplasm; plasma membrane; nerve terminal; cell junction; lateral plasma membrane; endosome
Molecular Function: protein domain specific binding; protein binding; gamma-catenin binding; beta-catenin binding; GTPase activating protein binding; ankyrin binding; calcium ion binding; cell adhesion molecule binding; glycoprotein binding; protein phosphatase binding
Biological Process: response to drug; intercellular junction assembly and maintenance; regulation of immune response; extracellular matrix organization and biogenesis; apoptosis; positive regulation of transcription, DNA-dependent; response to toxin; regulation of caspase activity; trophectodermal cell differentiation; regulation of water loss via skin; extracellular matrix disassembly; cell-cell adhesion; synaptogenesis; sensory perception of sound; pituitary gland development; calcium-dependent cell-cell adhesion; protein metabolic process; positive regulation of transcription factor import into nucleus; negative regulation of cell-cell adhesion; homophilic cell adhesion; protein homooligomerization; neurite development; cell structure disassembly during apoptosis; negative regulation of epithelial cell proliferation
Disease: Gastric Cancer, Hereditary Diffuse; Prostate Cancer; Breast Cancer; Ovarian Cancer; Endometrial Cancer
Product References and Citations for anti-CDH1 antibody
Frixen, U. H., Behrens, J., Sachs, M., Eberle, G., Voss, B., Warda, A., Lochner, D., and Birchmeier, W. (1991). E-cadherin-mediated cell-cell adhesion prevents invasiveness of Human carcinoma cells, J Cell Biol 113, 173-85. Schipper, J. H., Frixen, U. H., Behrens, J., Unger, A., Jahnke, K., and Birchmeier, W. (1991). E-cadherin expression in squamous cell carcinomas of head and neck: inverse correlation with tumor dedifferentiation and lymph node metastasis. Cancer Res 51, 6328-6337. Mayer, B., Johnson, J. P., Leitl, F., Jauch, K. W., Heiss, M. M., Schildberg, F. W., Birchmeier, W., and Funke, I. (1993). E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegRation. Cancer Res 53, 1690-1695. Moll, R., Mitze, M., Frixen, U. H., and Birchmeier, W. (1993). Differential loss of E-cadherin expression in infiltRating ductal and lobular breast carcinomas, Am J Pathol 143, 1731-42. Bohm, M., Totzeck, B., Birchmeier, W., and Wieland, I. (1994). Differences of E-cadherin expression levels and patterns in primary and metastatic Human lung cancer. Clin Exp Metastasis 12, 55-62. Otto, T., Birchmeier, W., Schmidt, U., Hinke, A., Schipper, J., Rubben, H., and Raz, A. (1994). Inverse relation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with bladder carcinomas. Cancer Res 54, 3120-3123. Zschiesche, W., Schonborn, I., Behrens, J., Herrenknecht, K., Hartveit, F., Lilleng, P., and Birchmeier, W. (1997). Expression of E-cadherin and Catenins in invasive mammary carcinomas. Anticancer Res 17, 561-567. Ghadimi, B. M., Behrens, J., Hoffmann, I., Haensch, W., Birchmeier, W., and Schlag, P. M. (1999). Immunohistological analysis of E-cadherin, alpha-, beta- and gamma-Catenin expression in colorectal cancer: impliCations for cell adhesion and signaling. Eur J Cancer 35, 60-65.
Research Articles on CDH1
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Products associated with anti-CDH1 antibody
Pathways associated with anti-CDH1 antibody
Diseases associated with anti-CDH1 antibody
Organs/Tissues associated with anti-CDH1 antibody
|